SCHEMBL9796337

SCHEMBL9796337

CC(=O)Nc1nnc(S(=O)(=O)Nc2nnc(S(N)(=O)=O)s2)s1

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 17/20 0.82
CA2 P00918 17/20 0.82
CA9 Q16790 10/20 0.82
CA4 P22748 6/20 0.82
CA12 O43570 2/20 0.82
CA3 P07451 2/20 0.82
CA6 P23280 2/20 0.82
CA5A P35218 2/20 0.82
CA7 P43166 2/20 0.82
CA13 Q8N1Q1 2/20 0.82
CA14 Q9ULX7 2/20 0.82
CA5B Q9Y2D0 2/20 0.82
MEN1 O00255 1/20 0.82
CA11 O75493 1/20 0.82
THRB P10828 1/20 0.82
BLM P54132 1/20 0.82
KMT2A Q03164 1/20 0.82
SMN1; SMN2 Q16637 1/20 0.82
TDP1 Q9NUW8 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetazolamide SCHEMBL23219 0.91 CA1 (1.00) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL2557036 0.91 CA1 (1.00) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL2845106 0.89 CA1 (0.97) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL30094028 0.89 CA1 (0.97) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL28346552 0.89 CA1 (0.97) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL1998362 0.89 CA1 (0.97) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL15513954 0.89 CA1 (0.97) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL40812 0.89 CA1 (0.97) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL11301585 0.89 CA1 (0.97) CA1CA2CA9CA4CA12
Acetazolamide SCHEMBL20553201 0.88 CA1 (0.93) CA1CA2CA9CA4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4990523-A Treatment of chronic inflammatory joint disease with arylsulfonamides A. H. ROBINS COMPANY, INCORPORATED (US) 1991-02-05 US disclosed
WO-1990015600-A2 TREATMENT OF CHRONIC INFLAMMATORY JOINT DISEASE WITH ARYLSULFONAMIDES A.H. ROBINS COMPANY, INCORPORATED (US) 1990-12-27 WO disclosed